Agenus to Webcast Annual Meeting of Stockholders
June 22 2015 - 5:41PM
Business Wire
Agenus Inc. (NASDAQ: AGEN), an immunology company developing
innovative treatments for cancers and other diseases, invites
investors and the general public to its Annual Meeting of
Stockholders to begin at 5:00 p.m. ET on Wednesday, June 24, 2015.
The meeting will be held at the company’s headquarters located at 3
Forbes Road, Lexington, MA 02421. Registration for attendees starts
at 4:30 p.m. ET.
A live webcast will be accessible from the company’s website at
http://www.agenusbio.com/webcast and will be archived and available
for replay within twenty-four hours after the meeting.
About Agenus
Agenus is an immunology company developing a series of
Checkpoint Modulators for the treatment of patients with cancer,
infectious diseases, and other immune disorders, heat shock protein
(HSP)-based vaccines, and immune adjuvants. These programs are
supported by three separate technology platforms. Agenus’ internal
and partnered checkpoint modulator programs target GITR, OX40,
CTLA-4, LAG-3, TIM-3, PD-1 and other undisclosed programs. The
company’s proprietary discovery engine Retrocyte DisplayTM is used
to generate fully human and humanized therapeutic antibody drug
candidates. The Retrocyte Display platform uses a high-throughput
approach incorporating IgG format human antibody libraries
expressed in mammalian B-lineage cells. Agenus recently acquired a
powerful yeast antibody display platform termed SECANT®, developed
by Celexion, LLC. SECANT allows rapid generation of soluble,
full-length human antibodies. SECANT and Agenus’ mammalian antibody
display platform have complementary strengths and further bolster
Agenus’ abilities to generate and optimize fully human monoclonal
antibodies. Agenus’ heat shock protein-based vaccines have
completed Phase 2 studies in newly diagnosed glioblastoma
multiforme, and in the treatment of herpes simplex viral infection;
the heat shock protein-based vaccine platform can generate
personalized as well as off the shelf products. The company’s QS-21
Stimulon® adjuvant platform is extensively partnered with
GlaxoSmithKline and with Janssen Sciences Ireland UC and includes
several candidates in Phase 2 trials, as well as shingles and
malaria vaccines which have successfully completed Phase 3 clinical
trials. For more information, please visit www.agenusbio.com, or
connect with the company on Facebook, LinkedIn, Twitter and
Google+; information that may be important to investors will be
routinely posted in these locations.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150622006426/en/
Media:BMC CommunicationsBrad Miles,
646-513-3125bmiles@bmccommunications.comorInvestors:Argot
PartnersAndrea Rabney/Jamie Maarten,
212-600-1902andrea@argotpartners.comjamie@argotpartners.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024